TY - JOUR
KW - Humans
KW - Retrospective Studies
KW - England/epidemiology
KW - *Nebulizers and Vaporizers
KW - chronic obstructive pulmonary disease
KW - Exacerbation
KW - Ff/umec/vi
KW - Healthcare cost
KW - Sitt
AU - A. Ismaila
AU - K. Rothnie
AU - R. Wood
AU - V. Banks
AU - L. Camidge
AU - A. Czira
AU - C. Compton
AU - R. Sharma
AU - S. Millard
AU - O. Massey
AU - D. Halpin
AD - Value Evidence and Outcomes, R&D Global Medical, GSK, 1250 South Collegeville Road, Collegeville, PA, USA. afisi.s.ismaila@gsk.com.
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada. afisi.s.ismaila@gsk.com.
Value Evidence and Outcomes, R&D Global Medical, GSK, London, UK.
Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UK.
Integrated Evidence Generation (Women's Health Care), Bayer PLC, Reading, UK.
Global Medical, GSK, London, UK.
P1vital Limited, Wallingford, Oxfordshire, UK.
College of Medicine and Health, University of Exeter Medical School, University of Exeter, Exeter, UK.
AN - 37749551
BT - Respir Res
C2 - PMC10521462
DO - 10.1186/s12931-023-02523-1
DP - NLM
ET - 2023/09/26
LA - eng
M1 - 1
N1 - 1465-993x
Ismaila, Afisi S
Orcid: 0000-0002-2876-8308
Rothnie, Kieran J
Orcid: 0000-0003-4279-1624
Wood, Robert P
Orcid: 0000-0002-6977-435x
Banks, Victoria L
Orcid: 0000-0002-0087-7641
Camidge, Lucinda J
Orcid: 0000-0001-8056-054x
Czira, Alexandrosz
Orcid: 0000-0002-3395-6186
Compton, Chris
Orcid: 0000-0002-7564-5343
Sharma, Raj
Millard, Shannon N
Orcid: 0000-0001-9161-4259
Massey, Olivia
Halpin, David M G
Orcid: 0000-0003-2009-4406
Journal Article
England
Respir Res. 2023 Sep 25;24(1):229. doi: 10.1186/s12931-023-02523-1.
PY - 2023
SN - 1465-9921 (Print)1465-9921
EP - 229
T2 - Respir Res
TI - Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
VL - 24
ER -